Le GORTEC Achieves Landmark Success in Head and Neck Cancer Treatment Trial Le GORTEC announces groundbreaking results from the NIVO POST OP trial, showing enhanced disease-free survival for advanced head and neck cancer patients treated with nivolumab.

Le GORTEC Achieves Landmark Success in Head and Neck Cancer Treatment Trial #France #Cancer_Treatment #GORTEC #Nivolumab #Tours

GORTEC Announces Landmark Success in Phase 3 Study for Head and Neck Cancer GORTEC has declared significant results from the NIVOPOSTOP GORTEC 2018-01 study, showing Nivolumab's effectiveness in enhancing disease-free survival for high-risk head and neck cancer patients.

GORTEC Announces Landmark Success in Phase 3 Study for Head and Neck Cancer #France #GORTEC #Nivolumab #Head_and_Neck_Cancer #Tours

GORTEC's Phase 3 Trial Shows Promising Results for Head and Neck Cancer Treatment GORTEC announces significant findings from their Phase 3 trial on nivolumab for head and neck cancer, marking a breakthrough in treatment options.

GORTEC's Phase 3 Trial Shows Promising Results for Head and Neck Cancer Treatment #USA #GORTEC #Nivolumab #Head_and_Neck_Cancer #Tours

GORTEC's Phase 3 Trial Demonstrates Breakthrough in Head and Neck Cancer Treatment GORTEC has announced successful results from its Phase 3 trial, NIVOPOSTOP GORTEC 2018-01, showcasing improved outcomes for head and neck cancer patients.

GORTEC's Phase 3 Trial Demonstrates Breakthrough in Head and Neck Cancer Treatment #France #GORTEC #Nivolumab #Head_and_Neck_Cancer #Tours